{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Total Deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 64.5 months (treatment duration ranged from 0.7 to 63.5 months).\n\nDeaths post treatment survival follow up were collected after the on- treatment period, up to approx. 7 years.","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"},{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG001","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Clinical Database Population: All treated participants.","reportingStatus":"POSTED","timeFrame":"approx. 64.5 months, approx. 7 years","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}